Regenerative Agriculture: A Sustainable ESG Strategy

Environmental, social, and governance (ESG) business practices once gave businesses a competitive edge with consumers, clients, investors, and stakeholders. However, the tide has turned. Companies no longer have the luxury of designing and implementing ESG strategies when it’s convenient. In today’s world, businesses are expected to do more to protect the environment and support evolving societal expectations. A promising solution to addressing environmental challenges is the practice of regenerative agriculture 

E2B: Energy to Business host Daniel J. Litwin caught up with Patrick Long, Director in Opportune LLP’s Process & Technology practice, and Rick Marriner, President, and Chief Operating Officer of Standard Soil, to discuss how regenerative agriculture practice can play a crucial role in addressing environmental challenges and how it fits within the broader scope of ESG.

Together, agriculture, land use, and deforestation represent the second-largest source of greenhouse gas emissions globally and the primary driver of biodiversity loss. Healthy soils can sequestrate carbon, support biodiversity, preserve water, and improve the resilience of agricultural yields, bringing healthy food while ensuring a sustainable source of income for millions. Regenerative agriculture is an opportunity to close the carbon loop.

For example, Standard Soil is embracing natural patterns of herding to transform agriculture. As Marriner puts it, “stepping back to move forward.” The company wants to reinvent agriculture with a focus on the ranching industry. By rotating cows and concentrating on different sections of land at various times, the soil and grass can remain healthy.

Feeding in rotation across the pasture is also known as mob grazing. Animals munch on the grass but not so much that they eat down to the roots and not so selectively that some grass dies off. Moving the animals in this way “allows the land to rebound and regenerate,” explains Marriner. The moving and shifting of cattle give grass new life. Simply put, a focus on growing better soil grows more, better grass, which produces more and better beef, faster.

While going green used to give a company an edge, it has now become standard practice today. This practice is also being considered and applied throughout the global supply chain.

“One of the key ingredients that have intersected with supply chains, my area of focus, has been around ESG with a huge emphasis on the environment and making sure that we truly understand and are cognizant of the carbon footprint that is out there,” Long says. “It’s great to find companies that are innovative like the one that Rick is working with that are doing something about it to create net positive benefits overall.”  

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More